The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML

Mutated nucleophosmin 1 (NPM1) is the most common genetic alteration in acute myeloid leukemia (AML), found in ∼30% of cases. Although mutations in this gene are considered favorable according to current risk stratification guidelines, a large fraction of patients will experience relapse, demonstrat...

Descripción completa

Detalles Bibliográficos
Autores principales: von Palffy, Sofia, Thorsson, Hanna, Peña-Martínez, Pablo, Puente-Moncada, Noelia, Sandén, Carl, Blom, Anna M., Henningsson, Rasmus, Juliusson, Gunnar, King, Ben, Landberg, Niklas, Lazarevic, Vladimir, Orsmark-Pietras, Christina, Rissler, Marianne, Rissler, Vendela, Ågerstam, Helena, Järås, Marcus, Lilljebjörn, Henrik, Fioretos, Thoas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111354/
https://www.ncbi.nlm.nih.gov/pubmed/36383712
http://dx.doi.org/10.1182/bloodadvances.2022007682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111354/
https://www.ncbi.nlm.nih.gov/pubmed/36383712
http://dx.doi.org/10.1182/bloodadvances.2022007682

Ejemplares similares